No Detail Found!

Efficacy analysis of vincristine, adriamycin, dexamethasone chemotherapy regimen combined with thalidomide in the treatment of multiple myeloma nephropathy and its impact on renal function factors

Author(s)
Jing Liu Department of Hematology, People's Hospital of Shangrao City,Shangrao, Jiangxi Province,China
Dian Liu Department of Nephrology, People's Hospital of Shangrao City,Shangrao, Jiangxi Province,China
Lijuan Wang Department of Nephrology, People's Hospital of Shangrao City,Shangrao, Jiangxi Province,China
Abstract
Myeloma nephropathy is a rare but challenging disease. This study aimed to evaluate the efficacy and renal functional outcomes of the VAD chemotherapy regimen and thalidomide treatment for myeloma nephropathy. From August 2022 to December 2023, a total of 94 patients were admitted to People's Hospital of Shangrao City. Patients were randomly assigned to Group C (VAD chemotherapy) and Group O (VAD chemotherapy plus thalidomide). Comparisons of renal function, treatment outcomes, and patient characteristics indicated that disease control and overall efficacy were significantly better in Group O (P<0.05). Compared with Group C, Group O also had greater reductions in serum creatinine, blood urea nitrogen, retinol-binding protein, M-protein, bone marrow plasma cells, and 24-hour proteinuria (P<0.05). Hemoglobin levels were significantly higher in Group O (P<0.05), and adverse reactions were significantly lower (P<0.05). The combination of VAD chemotherapy and thalidomide improved the therapeutic effects and renal function in myeloma nephropathy, supporting further exploration of this therapy.
Publication Details
Page(s) 61-70
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 1, Year: 2025

Request the full text from PASTIC

Keywords
Renal function, Thalidomide, Myeloma nephropathy, quantitative proteinuria, VAD chemotherapy regimen
References
Bai J,Wang JL,Yang Y,Zhang WG,Wang FX,Zhang L,Chen HL,Wang XM,Feng Y,Shen YD,Huang LJ,He AL .2019 .Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens. Hematology, 24(1) : 387-391.
Blue B,Pierre A,Mikhael J .2023 .Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma. Clin. Lymphoma Myeloma Leuk. , 23(9) : 651-659.
Bridoux F,Leung N,Belmouaz M,Royal V,Ronco P,Nasr SH,Fermand JP,Kidney International .2021 .Management of acute kidney injury in symptomatic multiple myeloma. Kidney Int, 99(3) : 570-580.
Costa BA,Mouhieddine TH,Richter J .2022 .What's old is new: The past, present and future role of thalidomide in the modern-day management of multiple myeloma. Target Oncol., 17(4) : 383-405.
Dimopoulos MA,Merlini G,Bridoux F,Leung N,Mikhael J,Harrison SJ,Kastritis E,Garderet L,Gozzetti A,van de Donk NWCJ,Weisel KC,Badros AZ,Beksac M,Hillengass J,Mohty M,Ho PJ,Ntanasis-Stathopoulos I,Mateos MV,Richardson P,Blade J,Moreau P,San-Miguel J,Munshi N,Rajkumar SV,Durie BGM,Ludwig H,Terpos E .2023 .Management of multiple myeloma-related renal impairment: Recommendations from the International Myeloma Working Group. , 24(7) : e293-e311.
Drummond PLM,Santos RMMD,Reis AMM,Malta JS,Silveira LP,Costa IHFD .2023 .Real-world effectiveness and safety of multiple myeloma treatments based on thalidomide and bortezomib: A retrospective cohort study from 2009 to 2020 in a Brazilian metropolis. Cancer Epidemiol, 85 : 102377.
Hanamura I .2022 .Multiple myeloma with high-risk cytogenetics and its treatment approach. Int. J. Hematol., 115(6) : 762-777.
Iijima T,Sawa N,Nakayama Y,Oba Y,Ikuma D,Mizuno H,Yamanouchi M,Suwabe T,Wake A,Kono K,Hoshino J,Ubara Y,Ohashi K Y .2022 .Vincristine. doxorubicin and dexamethasone induction before autologous stem cell transplantation in patients with AL amyloidosis: A retrospective comparison with frontline stem cell transplantation. Intern Med, 61(19) : 2853-2860.
Kuno H,Kanzaki G,Sasaki T,Haruhara K,Okabe M,Yokote S,Koike K,Tsuboi N,Yokoo T .2023 .High albumin clearance predicts the minimal change nephrotic syndrome relapse. Kidney360, 4(6) : e787-e795.
Mene P,Stoppacciaro A,Lai S,Festuccia F S .2022 .Light chain cast nephropathy in multiple myeloma: Prevalence, impact and management challenges. Int. J. Nephrol. Renovasc. Dis., 15 : 173-183.
Miki K,Shimamura Y,Maeda T,Moniwa N,Ogawa Y,Shimizu T,Hayashi T,Sakai H,Takizawa H H .2023 .Successful renal recovery from multiple myelomaassociated crystalline light chain cast nephropathy and accompanying acute kidney injury with early use of bortezomib-based therapy: A case report and literature review. CEN Case Rep, 12(1) : 56-62.
Nasr SH,Kudose S,Javaugue V,Harel S,Said SM,Pascal V,Stokes MB,Vrana JA,Dasari S,Theis JD,Osuchukwu GA,Sathick IJ,Das A,Kashkouli A,Suchin EJ,Liss Y,Suldan Z,Verine J,Arnulf B,Talbot A,Sethi S,Zaidan M,Goujon JM,Valeri AM,Mcphail ED,Sirac C,Leung N,Bridoux F,D'Agati VD .2023 .Pathological characteristics of light chain crystalline podocytopathy. Kidney Int, 103(3) : 616-626.
Ojo AS,Asemota J,Ojukwu S,Rajeh A,Bot A,Smith CJ,Laziuk K,Saleh M K .2022 .B-cell lymphomaassociated hemophagocytic lymphohistiocytosis: A case report. Oncol. Lett., 24(2) : 246.
Peng YF,Peng HT,Ke WB .2023 .(Noisy-le-. grand), 69(5) : 58-62.
Ravichandran S,Hall A,Jenner M,Garg M,Kishore B,Lachmann H,Gillmore J,Pitchford A,Oughton JB,Mahmood S,Sachchithantham S,Hawkins P,Brown S,Wechalekar A .2023 .A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis. Amyloid, 30(3) : 290-296.
Shi KW,Yuan SG,Huang Y,Li Z,Wang C,Liu H,Sun L,Liu FY,Zhu XJ .2022 .Clinic-pathological characteristics of rare tubulointerstitial diseases. Zhong Nan Da Xue Xue Bao Yi Xue Ban., 47(10) : 1365-1374.
Syed YY .2023 .Selinexor-bortezomib-dexamethasone: A review in previously treated multiple myeloma. Target Oncol., 18(2) : 303-310.
Tanimura A,Hirai R,Nakamura M,Takeshita M,Togano T,Sekine R,Hagiwara S,Miwa A .2020 .Efficacy of VRD (bortezomib., lenalidomide and dexamethasone) consolidation therapy and maintenance therapy with immunomodulatory drugs (thalidomide or lenalidomide) after autologous peripheral blood stem cell transplantation in the era of bortezomib-containing induction therapy - A Single Institution Experience. , 47(5) : 789-796.
Toriu N,Sawa N,Hiramatsu R,Mizuno H,Ikuma D,Sekine A,Hayami N,Sumida K,Yamanouchi M,Hasegawa E,Hoshino J,Takaichi K,Wake A,Ohashi K,Fujii T,Ubara Y .2020 .Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis. CEN Case Rep., 9(1), : 6-10.
Villa D,Hoster E,Hermine O,Klapper W,Szymczyk M,Bosly A,Unterhalt M,Rimsza LM,Ramsower CA,Freeman CL,Scott DW,Gerrie AS,Savage KJ,Sehn LH,Dreyling M .2022 .Bendamustine or highdose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma. Blood Adv., 6(18) : 5285-5294.
Wang Y,Wang XY,Yu JY,Wu S,Xu ZG,Sun WX .2022 .Idiopathic membranous nephropathy with renal amyloidosis: A case report. Front Med, 9 : 986065.
Weng QJ,Xu J,Shen PY,Xu T,Gao CN,Xie JY,Ren H,Pan XX H .2021 .Fulminant type I cryoglobulinemic glomerulonephritis with unique ultra structural plugs: A case report. Int. J. Hematol., 114(5) : 620-625.
Xing Y,Yan JP,Yu ZX,Zhao J,Wang YW,Li XY,Qin YL,Sun SR .2022 .High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury. Front. Oncol., 12 : 1024133.
Xu C,Liang T,Liu J,Fu YF .2022 .RAB39B as a Chemosensitivity-Related biomarker for diffuse large B-Cell lymphoma. , 13 : 931501.
Yıkılmaz AS,Akinci S,Bakanay SM,Dilek I .2020 .VAD chemotherapy versus bortezomib containing regimens as remission induction for ASCT in multiple myeloma: A single center experience. Int. J. Hematol. Oncol. Stem. Cell Res, 14(4) : 248-256.
Yong ZH,Yu XJ,Lin ZS,Zhou FD,Cen XN,Wang SX,Zhao MH .2021 .Myeloma cast nephropathy with diffuse amyloid casts without systemic amyloidosis: two cases report. BMC Nephrol, 22(1) : 6.
Zaffanello M,Pietrobelli A,Nosetti L,Piacentini G,Ferrante G,Piazza M,Guzzo A,Antoniazzi F A .2022 .Worldwide interest in vitamin D, negative effects on kidneys and bone density: Analysis of google trends data. J. Biol. Regul. Homeost. Agents, 36(6) : 1741-1747.
Zhang S,Cui D,Tang M,Yang G,Yard B,Hu H,Wu Y,Zhang Q Y .2023 .Serum and urinary carnosinase-1 correlate with kidney function and inflammation. Amino Acids, 55(1) : 89-100.
0

Citations

0

Downloads

91

Views